Unbreak My Heart: Progress Towards Personalized Arrhythmia Treatment-Can Polygenic Risk Scores Help Personalize Antiarrhythmic Therapy? (Presenter: Christopher H. Newton-Cheh, MD, MPH)

Can Polygenic Risk Scores Help Personalize Antiarrhythmic Therapy? (Presenter: Christopher H. Newton-Cheh, MD, MPH)

Video Transcription

Video Summary

Dr. Christopher Kuhn discusses the use of risk scores and polygenic risk scores to personalize antiarrhythmic therapy. He explains that genome-wide association studies have been successful in identifying common genetic variants related to intermediate traits or risk factors for sudden cardiac death, such as QT prolongation. Dr. Kuhn highlights two common genetic variants that have been studied: a variant in KCNE1 and a variant in the region of nitric oxide synthase one adapter protein (NOS1AP). These variants have been associated with a longer QT interval, and in some cases, an increased risk of drug-induced arrhythmia or Torsade de Pointes. Dr. Kuhn then discusses the development of polygenic risk scores, which aggregate the effects of multiple genetic variants to predict an individual's risk of drug-induced Torsade de Pointes. He presents findings from a study that demonstrated the predictive ability of a polygenic risk score using 61 genetic variants and suggests that these scores could be used to identify individuals at risk and guide the development of safer medications.

Meta Tag

Lecture ID 15811

Location Room 213

Presenter Christopher H. Newton-Cheh, MD, MPH

Role Invited Speaker

Session Date and Time May 10, 2019 10:30 AM - 12:00 PM

Session Number S-053

Keywords

risk scores

polygenic risk scores

personalize antiarrhythmic therapy

genome-wide association studies

genetic variants

Torsade de Pointes